The Cardiac Society of Australia and New Zealand supports catheter ablation in selected patients as a Class 1 indication for paroxysmal atrial fibrillation and a Class 2A indication for more persistent forms. This is in accordance with most recent European and American guidelines, and is supported in the Australasian environment by two recent papers endorsed by the CSANZ. Currently there is significant inequity of access to these procedures and the CSANZ supports calls to redress this imbalance to ensure all patients have access to best practice.